|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Net revenues | |||||
| Cost of sales | |||||
| Gross profit | |||||
| Research and development expenses, net | |||||
| Selling and marketing expenses | |||||
| General and administrative expenses | |||||
| Intangible assets impairments | |||||
| Goodwill impairment | |||||
| Other asset impairments, restructuring and other items | |||||
| Legal settlements and loss contingencies | |||||
| Other loss (income) | |||||
| Operating income (loss) | |||||
| Financial expenses – net | |||||
| Income (loss) before income taxes | |||||
| Income taxes (benefit) | |||||
| Share in (profits) losses of associated companies – net | |||||
| Net income (loss) | |||||
| Net income (loss) attributable to redeemable and non-redeemable non-controlling interests | |||||
| Net income (loss) attributable to Teva | |||||
| Earnings (loss) per share attributable to ordinary shareholders: | |||||
| Basic | |||||
| Diluted | |||||
| Weighted average number of shares (in millions): | |||||
| Basic | |||||
| Diluted |
Loading...
